Genetic analysis of saliva may offer a noninvasive way to assess the risk of developing Parkinson’s disease, according to a saliva-based DNA study led by researchers at the University of the Basque Country (EHU) in Spain. The scientists found that molecular markers in saliva can reflect whole-body disease processes,…
Pharmather is advancing its ketamine-based treatment for Parkinson’s disease as the approval decision date of Aug. 9, 2025, set by the U.S. Food and Drug Administration (FDA) draws closer. If approved, the company plans to market the product under the brand name Ketarx and expand its use in neurological conditions,…
Target enrollment for a Phase 1b clinical study assessing the safety and tolerability of GT-02287 in people with Parkinson’s disease is complete, three months ahead of the original goal, the therapy’s developer said. After enrolling the first 16 participants, the Phase 1b clinical trial (NCT06732180) is recruiting up…
People in the prodromal, or presymptomatic, stage of Parkinson’s disease show increased immune activity, with T cells targeting the proteins PINK1 and alpha-synuclein at levels similar to those seen in patients already diagnosed with the neurodegenerative condition, a new study reports. These two proteins — PINK1 and alpha-synuclein —…
BioVie’s ongoing SUNRISE-PD clinical trial of bezisterim in early Parkinson’s disease uses a hybrid, decentralized approach to center patient experience and promote accessibility, according to the company. Parkinson’s disease patients often face barriers to accessing specialized care and participating in clinical trials due to delayed diagnosis, limited mobility, and…
A trio of prominent Parkinson’s disease advocacy groups are calling on the U.S. federal government to provide strong funding and support for the National Institutes of Health (NIH) — a federal agency that is a major driver of biomedical research around the world. The American Parkinson Disease Association,…
Copper supplementation that reaches the brain reduces the signs and symptoms of Parkinson’s disease in a mouse model, a study found. Researchers found that copper restored the function of SOD1, an antioxidant enzyme that’s prone to misfolding and forming toxic clumps, impairing the function of dopamine-producing nerve cells that…
Neuron23 has dosed the first participant in its Phase 2 clinical trial of NEU-411, an investigational treatment for early Parkinson’s disease that targets overactivity in the LRRK2 enzyme. The therapy may benefit individuals with genetic mutations or variations in the LRRK2 gene, which is a key contributor and…
People with Parkinson’s disease have altered levels of certain fat molecules, known as lipids, in their brains, and this may play a role in disease development and progression, a new study from the U.S. reports. The researchers used postmortem brain tissue samples to analyze changes in lipids in 40…
A three-year grant from Parkinson Canada will allow a Canadian researcher to investigate the mechanisms by which a recently found mutation in the RAB32 gene is linked to Parkinson’s disease. The $135,000 grant will allow Jay Penney, PhD, associate professor at the University of Prince Edward Island in…
Get regular updates to your inbox.
